ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
Geoff
G
Newman
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000592:standards; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D017671:Platinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D012107:Research Design / Q000592:standards; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D017671:Platinum Compounds; D043823:Taxoids; D016190:Carboplatin; D017239:Paclitaxel